Skip to main content

Table 3 Association between KSHV seropositivity or antibody levels and study population. KSHV seropositivity in adults

From: Variation in KSHV prevalence between geographically proximate locations in Uganda

Study Females 14-49 years Females 14–103 years Males 14–103 years
KSHV seropositivity *OR (95% CI), P value KSHV seropositivity *OR (95% CI), P value KSHV seropositivity *OR (95% CI), P value
EMaBSa 69% (806/1164) 1 69% (806/1164) 1   
GPCb 85% (1388/1638) 2.60 (1.92, 3.51), < 0.0001 87% (1905/2201) 2.61 (1.94, 3.52), < 0.0001 90% (1486/1657) 1
LaVIISWAc 79% (400/493) 1.69 (1.21, 2.36), 0.002 80% (425/519) 1.72 (1.22, 2.42), 0.002 88% (477/539) 0.71 (0.44, 1.15), 0.165
GHWPd 90% (361/402) 3.93 (2.74, 5.64), < 0.0001 90% (361/402) 3.9 (2.72, 5.59), < 0.0001   
  1. * Adjusted for age group and HIV serostatus. *OR: odds ratio. Logistic regression analysis was used for statistical analysis allowing for the survey design for the LaVIISWA trial. aEMaBS-Entebbe Mother and Baby Study, bGPC-General Population Cohort, cLaVIISWA-Lake Victoria Island Intervention Study on Worms and Allergy related diseases, dGHWP-Good Health for Women Project